Gene therapy pioneer James Wilson makes a comeback after disastrous start

jim wilson mini e x
Image: James Wilson

Twenty years ago, a young man named Jesse Gelsinger was injected with a large dose of gene-shuttling viruses designed in Wilson’s lab. The experimental treatment was created to treat a rare metabolic liver disease. The goal was to deliver a working copy of the teenager’s broken gene, but the viruses threw his immune system into overdrive. Four days after being treated, Gelsinger died. It was the first public tragedy of a highly hyped field.

As details about Gelsinger’s death emerged, the entire enterprise of gene therapy began to crumble. The Gelsinger family filed a lawsuit. Investor money dried up, and start-ups shuttered. Wilson found himself at the center of multiple investigations.

Related article:  Viewpoint: Netflix's new horror movie 'Eli' is a fright. But why did they have to 'tarnish gene therapy'?

Wilson’s downsized and outcast lab kept plugging away with a newfound focus on finding safer viruses. Their work led to the discovery and dissemination of new AAVs, including one used in the recently approved gene therapy Zolgensma, which saves the lives of infants born with an otherwise fatal neurological disease.

ADVERTISEMENT

And Zolgensma is just the beginning. By Penn’s latest count, some 42 companies are using AAVs that fall under Wilson’s patents, covering nearly 100 drug development programs.

Read full, original post: The redemption of James Wilson, gene therapy pioneer

Outbreak Daily Digest
Biotech Facts & Fallacies
GLP Podcasts
Infographic: Here’s where GM crops are grown around the world today

Infographic: Here’s where GM crops are grown around the world today

Do you know where biotech crops are grown in the world? This updated ISAAA infographics show where biotech crops were ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

* indicates required
Email Lists
Send this to a friend